Expertise in
2
conditions

Jae-sik S. Jang

Goyang, KR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Goyang, KR 

Overview

Jae-sik Jang practices in Goyang, Republic of Korea. Jang is highly rated in 2 conditions, according to our data. Their top areas of expertise are Coronary Heart Disease, Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Percutaneous Coronary Intervention (PCI), and Angioplasty.

Their clinical research consists of co-authoring 61 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Goyang, Republic of Korea
Other Locations
Busan, Republic of Korea
Haeundae, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Enrollment Status: Recruiting
Publish Date: January 02, 2026
Intervention Type: Procedure
Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Enrollment Status: Active_not_recruiting
Publish Date: January 02, 2026
Intervention Type: Device
Evaluation of Effectiveness and Safety of BIOFREEDOM™ FAMILY Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Evaluation of Effectiveness and Safety of BIOFREEDOM™ FAMILY Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Enrollment Status: Terminated
Publish Date: September 30, 2025
Intervention Type: Device
Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention
Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drugs: Tailored antithrombotic strategy, Conventional antithrombotic strategy
Study Phase: Phase 4
Perfusion CT Registry
Perfusion CT Registry
Enrollment Status: Completed
Publish Date: March 22, 2023
A Prospective, Open Label, Multi-center, Dual Arm, Randomized Trial : The ROTA-ISR (Debulking With Rotational Atherectomy Versus Balloon Angioplasty In Patients With In-stent Restenosis) Trial
A Prospective, Open Label, Multi-center, Dual Arm, Randomized Trial : The ROTA-ISR (Debulking With Rotational Atherectomy Versus Balloon Angioplasty In Patients With In-stent Restenosis) Trial
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial
A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial
Enrollment Status: Completed
Publish Date: November 30, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

61 Total Publications

Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.
Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.
Journal: Clinical therapeutics
Published: October 23, 2025

Frequently Asked Questions about Jae-sik S. Jang

Is Jae-sik S. Jang a top-rated expert for Coronary Heart Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Jae-sik S. Jang is classified as an Advanced expert for Coronary Heart Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jae-sik S. Jang participate in research or clinical trials?

Yes. Jae-sik S. Jang has published 61 articles and abstracts on conditions like Coronary Heart Disease. You can view a list of Jae-sik S. Jang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Jang's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile